

Myung Sun Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3373394/publications.pdf>

Version: 2024-02-01

18
papers

84
citations

1684188

5
h-index

1588992

8
g-index

19
all docs

19
docs citations

19
times ranked

110
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2023, 64, 722-724. | 1.3 | 1 |
| 2 | When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 151-152. | 3.5 | 1 |
| 3 | Artificial intelligence and magnetic resonance imaging may not make cancer screening better. <i>Journal of Cancer Policy</i> , 2022, 31, 100314. | 1.4 | 0 |
| 4 | Overall survival for oncology drugs approved for genomic indications. <i>European Journal of Cancer</i> , 2022, 160, 175-179. | 2.8 | 6 |
| 5 | Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia. <i>Case Reports in Hematology</i> , 2022, 2022, 1-5. | 0.4 | 5 |
| 6 | Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 1207-1211. | 5.2 | 12 |
| 7 | Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020. <i>International Journal of Cancer</i> , 2022, 150, 1905-1910. | 5.1 | 3 |
| 8 | Addressing Sex Disparities in Academic Oncology. <i>JAMA Oncology</i> , 2022, . | 7.1 | 0 |
| 9 | Persistent challenges with treating multiple myeloma early. <i>Blood</i> , 2021, 137, 456-458. | 1.4 | 17 |
| 10 | Approval and Coverage of Cancer Drugs in England, Canada, and the US. <i>JAMA Internal Medicine</i> , 2021, 181, 509. | 5.1 | 7 |
| 11 | Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. <i>European Journal of Cancer</i> , 2021, 155, 163-167. | 2.8 | 7 |
| 12 | Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature. <i>JAMA Internal Medicine</i> , 2021, . | 5.1 | 5 |
| 13 | New drugs and options can enhance patient outcomes: But can they also erode them?. <i>European Journal of Cancer</i> , 2021, 154, 1-3. | 2.8 | 1 |
| 14 | A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy. <i>Blood</i> , 2021, 138, 184-184. | 1.4 | 1 |
| 15 | The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. <i>JAMA Internal Medicine</i> , 2020, 180, 315. | 5.1 | 5 |
| 16 | US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. <i>Cancer</i> , 2020, 126, 4270-4272. | 4.1 | 3 |
| 17 | Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. <i>JAMA Network Open</i> , 2019, 2, e193981. | 5.9 | 7 |
| 18 | Cancer screening: A modest proposal for prevention. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 157-160. | 1.3 | 3 |